Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 16/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15014476 | 0.84 | ALDH1A1 (0.49) | FAAHTLR9TLR8TLR7WNT1 | |
| SCHEMBL12424319 | 0.82 | CYP2D6 (0.45) | TLR9TLR8TLR7WNT1GSK3B | |
| SCHEMBL12384853 | 0.81 | TLR8 (0.40) | FAAHTLR9TLR8TLR7WNT1 | |
| SCHEMBL18933195 | 0.81 | CYP2D6 (0.39) | FAAHTLR9TLR8TLR7WNT1 | |
| SCHEMBL18023854 | 0.80 | KMT2A (0.44) | TLR9TLR8TLR7WNT1GSK3B | |
| SCHEMBL17207710 | 0.80 | WNT1 (0.41) | FAAHTLR9TLR8TLR7WNT1 | |
| SCHEMBL3070225 | 0.78 | CYP2D6 (0.41) | TLR9TLR8TLR7WNT1GSK3B | |
| SCHEMBL18933193 | 0.77 | LTA4H (0.41) | FAAHTLR9TLR8TLR7WNT1 | |
| SCHEMBL17285987 | 0.77 | MC4R (0.42) | WNT1GSK3BDYRK1A | |
| SCHEMBL3076356 | 0.76 | HRH3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | FAAH 3633/4885TLR9 2536/4885TLR8 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.